Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
about
Bisphenol A and estradiol are equipotent in antagonizing cisplatin-induced cytotoxicity in breast cancer cellsTargeting abnormal DNA repair in therapy-resistant breast cancersRoles for miRNAs in endocrine resistance in breast cancerThe discovery and development of selective estrogen receptor modulators (SERMs) for clinical practiceAdvances in molecular imaging for breast cancer detection and characterizationEET signaling in cancerModulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cellsThe impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasisCytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogen-dependent breast cancer cell growth.Multimodality and nanoparticles in medical imagingThe HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.Estrogen stimulation of cell migration involves multiple signaling pathway interactionsEffects of aromatase inhibition and androgen activity on serotonin and behavior in male macaques.Stratified medicine in European Medicines Agency licensing: a systematic review of predictive biomarkersNew steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death.Acute administration of non-classical estrogen receptor agonists attenuates ischemia-induced hippocampal neuron loss in middle-aged female rats.Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities.Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy.GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cellsCircadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer.Non-viral nanocarriers for siRNA delivery in breast cancer.Cytochrome P450-derived eicosanoids: the neglected pathway in cancer.Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populationsScientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality.Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells.The FGF/FGFR axis as a therapeutic target in breast cancer.Beyond the one-locus-one-miRNA paradigm: microRNA isoforms enable deeper insights into breast cancer heterogeneity.Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231.Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.3D QSAR studies, pharmacophore modeling and virtual screening on a series of steroidal aromatase inhibitors.JunD and JunB integrate prostaglandin E2 activation of breast cancer-associated proximal aromatase promoters.Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale.Estrogen receptors and their implications in colorectal carcinogenesis.Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell deathLong-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells.Breast cancer - one term, many entities?
P2860
Q24596235-BF93374F-E416-482D-92D4-45880DDFDE6FQ24605455-90DCB6B7-93D8-425A-8C47-B64C82496988Q26783076-5D102309-6960-48F1-ACBD-FE2ECB11E65CQ26830744-50A8C4DF-494C-4285-885B-2197F105D0DDQ27000462-8420EEE4-9AA1-49D0-84C3-D836F78B046AQ28250730-31D068EF-2FA4-4C3F-9783-A916F1C58EAEQ28261025-D544E049-47DA-455A-9FF7-FCE2C433C6A8Q28388257-13E5B4AF-3977-4E14-B1F3-5033B7E72EEAQ30352693-72A28AC7-0CC9-4D44-AF59-8A1E361BA7ADQ30407070-F151FC6C-F286-4D58-9958-F85123297D81Q30425478-D18C8EB0-FFE9-419D-AA36-7687F2299B7FQ30429931-EA3A3D4F-4D65-4E37-B8B1-557605C11507Q30570465-AD93C6DC-E197-4675-AF97-BB8274BA7CA0Q30570744-88ED0807-223D-4109-AD9A-008AAC9580DAQ33354763-7CEBA676-1769-42A5-9DA4-B9F5E878C6DEQ33523047-9B89CA6A-ED06-43D1-9430-48A3141A1EC0Q33700933-8E175714-5D1C-44DA-9B99-C8A407280711Q33705490-4A390232-3771-4AD9-A015-7DE4DC84AE8CQ33754817-F3796D19-D2AD-405A-967D-D687242B8DFFQ33928138-0064D1F4-5FB7-4675-A041-275C69CE3B13Q33992390-B989AAAF-CA41-43C1-A73C-7D63AF8047F0Q34079608-1221A47B-B63A-4955-BF22-298712453B97Q34143118-5878D0AF-A755-4701-8E7D-0244E401382FQ34315889-90DAD61E-DE80-430A-BA86-2ADB6CAF3F5DQ34362281-B039D3C5-AF3C-40C7-A2D8-8EDE56B0967FQ34411166-7EB7C2E1-9120-4926-840C-650F268F10D0Q34495216-0BB2250D-C2D2-45CD-B5B6-25B6EB664D55Q34495412-B4B75D65-B15C-4046-BD2C-5F01AD71525FQ34545864-35650876-4D79-4953-BF94-94B9EFC9580EQ34674316-757CED0F-4D5B-49B3-8F24-660C1D06F40BQ34685559-BE59E51E-9711-4768-8FAF-EE1CE2C6BEC1Q34856420-EAE7111A-593B-47DD-9C63-2171681E38B4Q34908885-44CFA6F9-18DE-4930-B6B8-5061809961C8Q34914140-474CACCA-2776-42B8-BFD5-A81FA1B32991Q34978420-529503D9-E6F9-42AC-B94E-FA1E34E1AB40Q35023715-F56F977A-1D68-4E46-B530-D3D1A0E81D81Q35037282-97E3A118-1238-47CA-9DC8-6014B2158E4EQ35107727-FE7C5E58-6579-494B-B5D3-6D99A43CA375Q35234377-67E0A87C-6D86-4D1E-A5AD-BD69709B9B9EQ35370118-4BA08585-0821-462E-B3C3-46C121F2788E
P2860
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Development and evolution of t ...... d prevention of breast cancer.
@ast
Development and evolution of t ...... d prevention of breast cancer.
@en
type
label
Development and evolution of t ...... d prevention of breast cancer.
@ast
Development and evolution of t ...... d prevention of breast cancer.
@en
prefLabel
Development and evolution of t ...... d prevention of breast cancer.
@ast
Development and evolution of t ...... d prevention of breast cancer.
@en
P2860
P1433
P1476
Development and evolution of t ...... d prevention of breast cancer.
@en
P2093
Angela M H Brodie
V Craig Jordan
P2860
P356
10.1016/J.STEROIDS.2006.10.009
P577
2006-12-13T00:00:00Z